Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SON4PEM: sonlicromanol in post-COVID
2025-521866-92-01Phase 2Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-COVID syndrome comparing Sonlicromanol with Placebo (2 arms). Primary endpoint: Fatigue symptoms at week 13. Planned start Dec 2025; status: authorised.
02
Drugs
sonlicromanol
03
Conditions
post-COVID syndrome
Beyond the preview
Go deeper on 2025-521866-92-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521866-92-01.